Additionally, treatment with Maraviroc (Pfizer, New York, United States), a CCR5 antagonist approved by the FDA, improves motor recovery in rodent models of stroke and TBI by enhancing tissue preservation in the brain, attenuating inflammatory responses, and upregulating the levels of cognition-related signaling molecules to promote neural plasticity (Villanueva, 2019; Friedman-Levi et al., 2021). This evidence concerns the gene CCR5 and Stroke.